Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.
Biotechnology, Life Science, Pharmaceutical
You're a corporate or investor and looking for startups that are innovating in the same market as Pharvaris
? We're happy to assist you with our Startup Sourcing